notable

Autonomix Medical Inc. Covered in Benzinga Article Highlighting Innovative Nerve Treatment Technology

Source Node:
Time Stamp: April 15, 2024 1:26 PM - Modified On: April 15, 2024 - Published By:
Source Cluster:
Republished By Plato

  Company is targeting pancreatic cancer pain with advanced nerve detection and treatment technology New York, March 12, 2024 - (Plato Data) - Benzinga has published a new article on Autonomix Medical Inc. (NASDAQ: AMIX), featuring the company's groundbreaking approach to peripheral nervous system (PNS) disorders. The Benzinga article delves into the critical role of the PNS in human health and highlights how Autonomix Medical is pioneering with its catheter-based microchip sensing array technology. The article provides a comprehensive look at how Autonomix Medical is redefining treatment protocols for nerve-related

Alvara Protocol Raises $2.4M in Lightning Public Round

Source Node:
Time Stamp: March 19, 2024 12:15 PM - Modified On: March 19, 2024 - Published By:
Source Cluster:
Republished By Plato

  Alvara Protocol is looking set to play a substantial role in redefining how the world invests. Their groundbreaking infrastructure, that is set to be an industry first, leverages the ERC-7621 (BTS or Basket Token Standard) to facilitate the creation of fully decentralized tokenized cryptocurrency investment funds. Now, anyone can now become a fund manager with ease. The responsibility for managing funds is something that has long been gatekept. Reserved for institutions or those already financially established. This is no longer the case. Alvara are poised to empower the next

GDA Capital Acquires Omni3, Expands into Singapore with New Gaming Lead

Source Node:
Time Stamp: March 12, 2024 5:58 AM - Modified On: March 12, 2024 - Published By:
Source Cluster:
Republished By Plato

  [Singapore, March 12] — GDA Capital, a global leader in digital asset and blockchain technology investments and capital markets advisory, is excited to announce the acquisition of Omni3, a digital asset and disruptive technology advisory firm based in Singapore. This strategic move marks a significant milestone for GDA Capital as it extends its global footprint into the vibrant Asian market, with a dedicated commitment to establishing a full-time presence in Singapore. Nicholas Seah, the esteemed founder of Omni3, will be joining the GDA Capital team as the Gaming Lead,

D8X Re-Engineers DeFi Derivatives With Launch on Polygon zkEVM

Source Node:
Time Stamp: February 6, 2024 2:05 PM - Modified On: February 6, 2024 - Published By:
Source Cluster:
Republished By Plato

  Supported by Polygon Ventures, D8X targets institutional users with next-gen DEX engine, innovative features, novel white-label approach [Zug, Switzerland - Feb. 6, 2024] - D8X, an institutional-grade decentralized exchange (DEX) for derivatives, has launched on Polygon zkEVM, establishing a new benchmark for decentralized finance. With support from Polygon Ventures and other notable partners, D8X reconceives on-chain derivatives, starting from fundamental financial engineering and extending to its novel white-label business-to-business model–a first for Polygon zkEVM. Until now, users seeking the trading experience offered by D8X have had to resort to

Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate

Source Node:
Time Stamp: January 29, 2024 6:55 AM - Modified On: January 29, 2024 - Published By:
Source Cluster:
Republished By Plato

New York, Jan. 29, 2024 - (Plato Data) - Corbus Pharmaceuticals (NASDAQ:CRBP) jumped on Friday after announcing positive data from a small group of cancer patients who received its antibody-drug conjugate (ADC) CRB-701 in a Phase 1 trial. Citing a December data cut in patients with cancers expressing a tumor-associated antigen called nectin-4, Corbus (CRBP) said that CRB-701 led to an objective response rate (ORR) of 43%, including three partial responses. The data from the first eighteen participants who received the first six dose levels represented the readout, which was

Unveiling the Inaugural Global Protocol Report: A Comprehensive Analysis of Blockchain Protocols that is Poised to Aid WEB3 Decisions

Source Node:
Time Stamp: January 22, 2024 4:40 AM - Modified On: January 22, 2024 - Published By:
Source Cluster:
Republished By Plato

Crypto Oasis, Crypto Valley, the DLT Science Foundation and Inacta Ventures Join Forces in a Groundbreaking Initiative that Will Help Navigate the Blockchain Trilemma Highlights: The report has unprecedented transparency and clarity, granular insights, and an evolving analysis of DLT protocol attributes. It will help industry experts and novices gain foundational knowledge on DLT concepts, WEB3 ecosystem infrastructure, the evolution of the Blockchain landscape, and the role of capital, talent, infrastructure, and regulations in WEB3 innovation. The Global Protocol Report introduces a comprehensive framework for assessing the maturity of DLT

SUPER BOWL 2024: LAS VEGAS LEGENDS LIVE BRIDGING THE SUPERBOWL SPIRIT WITH A LEGENDARY EVENT AND METAVERSE INNOVATION

Source Node:
Time Stamp: January 9, 2024 10:03 AM - Modified On: January 9, 2024 - Published By:
Source Cluster:
Republished By Plato

Las Vegas, NV – January 9th 2024. As the Super Bowl fever grips Las Vegas, Legends Live is set to amplify this excitement with a one-of-a-kind event, Legends Live, on February 4th, 2024, at Vu Studios. This event, building up to the Super Bowl weekend, offers a unique blend of sports legends' stories and cutting-edge Metaverse streaming technology in partnership with TCG World. Legends Live presents a rare opportunity to hear from sports icons in the lead-up to one of the biggest sporting events of the year. The event will

Bracket Labs Announces $2 Million Pre-Seed Raise to Support the Launch of its ‘Passages’ Trading Platform

Source Node:
Time Stamp: January 4, 2024 2:04 PM - Modified On: January 4, 2024 - Published By:
Source Cluster:
Republished By Plato

PANAMA CITY FLA – January 4, 2024 – Bracket Labs completed a $2 million pre-seed fundraise round to support the launch of "Passage," a volatility trading product available on the project’s BracketX trading platform. The debut of the range-bound product makes trading long and short volatility entirely on-chain easy for traders of all levels. In June 2023, Bracket Labs completed Binance Labs’ Season 5 Incubation Program and received investment from Binance Labs. In addition to completing the Incubation Program, Bracket Labs completed its pre-seed investment round from other notable crypto

IQPay announces Lead Investor Steven Freidmutter Joins IQPay’s Advisory Board

Source Node:
Time Stamp: October 31, 2023 6:13 AM - Modified On: October 31, 2023 - Published By:
Source Cluster:
Republished By Plato

  Johannesburg 25 October 2023 -, IQPay an innovative force in the fintech landscape, is elated to announce that Steven Freidmutter has officially joined its advisory board. Adding to this significant appointment, Freidmutter is also stepping in as the lead investor for IQPay, marking a milestone in the company's journey. Steven Freidmutter brings to IQPay an impressive track record of experience, presence and credibility. Freidmutter's journey continues to defy conventions. His recent appointment as a partner and founding advisory board member of the Boston-based VC fund Erez Capital is a

Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases

Source Node:
Time Stamp: October 13, 2023 5:17 AM - Modified On: October 13, 2023 - Published By:
Source Cluster:
Republished By Plato

  In the United States, heart disease accounts for a significant number of deaths every year, with cardiovascular disease being the primary concern. Factors like lifestyle choices and unforeseen circumstances contribute to its prevalence. Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the heart's lining) are two inflammatory heart conditions primarily linked to immunological reactions from viral infections and mRNA vaccines. Though considered rare, awareness of these conditions is growing, especially among younger populations. Recent research in Science Immunology highlighted an increase in cytokine production leading to myocarditis

Gain Therapeutics Achieves Remarkable Breakthrough in Parkinson’s Disease Research

Source Node:
Time Stamp: August 29, 2023 8:20 AM - Modified On: August 29, 2023 - Published By:
Source Cluster:
Republished By Plato

Gain Therapeutics, Inc. (Nasdaq: GANX), a pioneering biotechnology company specializing in innovative allosteric small molecule therapies, has made significant strides in the fight against Parkinson's disease (PD). The Company's lead drug candidate, GT-02287, has demonstrated extraordinary potential in mitigating the effects of Parkinson's disease across two distinct preclinical models of the ailment. These findings suggest that GT-02287 has the capacity to alleviate Parkinson's disease pathology and enhance motor function. A notable highlight is the substantial reduction of plasma Neurofilament Light Chain (NfL) levels, an emerging biomarker for neurodegeneration. This advancement